Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD20-Immunotargeting in Metastatic Melanoma Patients- A Prospective, Open Label, Sequential Pilot Study

NCT01376713 is registered in ClinicalTrials.gov with Medical University of Vienna as lead sponsor.

NCT NCT01376713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01376713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD20-Immunotargeting in Metastatic Melanoma Patients- A Prospective, Open Label, Sequential Pilot Study
Lead sponsor
Medical University of Vienna
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
May 31, 2015
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii melanoma, stage iv melanoma